Spero Therapeutics (SPRO) Cash from Financing Activities (2016 - 2023)
Spero Therapeutics' (SPRO) quarterly Cash from Financing Activities came in at $1000.0 in Q4 2023, down 99.99% YoY from $14.2 million in Q4 2022, and down 99.55% on a QoQ basis from $220000.0 in Q3 2023.
Spero Therapeutics (SPRO) Cash from Financing Activities (2016 - 2023) Analysis & Trends
Spero Therapeutics (SPRO) has 8 years of Cash from Financing Activities data on file, last reported at $1000.0 in Q4 2023.
- Quarterly Cash from Financing Activities fell 99.99% year-over-year to $1000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2024 was $221000.0 (changed 0.0% YoY) and the FY2023 annual result came in at $221000.0, up 100.75% from the prior year.
- Cash from Financing Activities slipped to $1000.0 in Q4 2023, from $220000.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $77.2 million in Q3 2020 to a low of -$53.7 million in Q2 2022.
- A 5-year average of $11.2 million and a median of $5.9 million in 2019 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2020 — Cash from Financing Activities jumped 772050.0% — and 2022, when it plunged 32050.6%.
- Tracing SPRO's Cash from Financing Activities over 5 years: stood at $5.6 million in 2019, then surged by 187.37% to $16.1 million in 2020, then soared by 212.92% to $50.3 million in 2021, then slumped by 71.84% to $14.2 million in 2022, then sank by 99.99% to $1000.0 in 2023.
- The last three Cash from Financing Activities figures came in at $1000.0 (Q4 2023), $220000.0 (Q3 2023), and $14.2 million (Q4 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Spero Therapeutics | 70.72 Mn | 19.95 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 1,000.00 |
| Dec 31, 2023 | 1,000.00 |
| Sep 30, 2023 | 220,000.00 |
| Sep 30, 2023 | 220,000.00 |
| Dec 31, 2022 | 14.18 Mn |
| Dec 31, 2022 | 14.18 Mn |
| Sep 30, 2022 | 6.13 Mn |
| Sep 30, 2022 | 6.13 Mn |
| Jun 30, 2022 | -53.68 Mn |
| Jun 30, 2022 | -53.68 Mn |
| Mar 31, 2022 | 3.81 Mn |
| Mar 31, 2022 | 3.81 Mn |
| Dec 31, 2021 | 50.35 Mn |
| Dec 31, 2021 | 50.35 Mn |
| Sep 30, 2021 | 29.22 Mn |
| Sep 30, 2021 | 29.22 Mn |
| Jun 30, 2021 | 168,000.00 |
| Jun 30, 2021 | 168,000.00 |
| Mar 31, 2021 | 4.31 Mn |
| Mar 31, 2021 | 4.31 Mn |